WO1999062505A3 - Method for treating neurodegenerative disorders - Google Patents

Method for treating neurodegenerative disorders Download PDF

Info

Publication number
WO1999062505A3
WO1999062505A3 PCT/US1999/011702 US9911702W WO9962505A3 WO 1999062505 A3 WO1999062505 A3 WO 1999062505A3 US 9911702 W US9911702 W US 9911702W WO 9962505 A3 WO9962505 A3 WO 9962505A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurodegenerative disorders
treating neurodegenerative
subject
treating
amyloid
Prior art date
Application number
PCT/US1999/011702
Other languages
French (fr)
Other versions
WO1999062505A2 (en
Inventor
Allen B Reitz
David A Demeter
Daniel H S Lee
Hoau-Yan Wang
Robert H Chen
Tina Morgan Ross
Malcolm K Scott
Carlos R Plata-Salaman
Original Assignee
Ortho Mcneil Pharm Inc
Allen B Reitz
David A Demeter
Daniel H S Lee
Wang Hoau Yan
Robert H Chen
Tina Morgan Ross
Malcolm K Scott
Plata Salaman Carlos R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc, Allen B Reitz, David A Demeter, Daniel H S Lee, Wang Hoau Yan, Robert H Chen, Tina Morgan Ross, Malcolm K Scott, Plata Salaman Carlos R filed Critical Ortho Mcneil Pharm Inc
Priority to CA2333951A priority Critical patent/CA2333951C/en
Priority to JP2000551761A priority patent/JP4637351B2/en
Priority to DE69913520T priority patent/DE69913520T2/en
Priority to AT99928342T priority patent/ATE255888T1/en
Priority to EP99928342A priority patent/EP1083889B1/en
Priority to DK99928342T priority patent/DK1083889T3/en
Priority to AU45433/99A priority patent/AU765142B2/en
Publication of WO1999062505A2 publication Critical patent/WO1999062505A2/en
Publication of WO1999062505A3 publication Critical patent/WO1999062505A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/32—Esters thereof
    • C07F9/3258—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3282—Esters with hydroxyaryl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention is directed to a method of treating a neurodegenerative disorder in a subject in need thereof which comprises administering to the subject an amount of a compound effective to inhibit the interaction of amyloid-beta with alpha-7 nicotinic acetylcholine receptors.
PCT/US1999/011702 1998-06-01 1999-05-27 Method for treating neurodegenerative disorders WO1999062505A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2333951A CA2333951C (en) 1998-06-01 1999-05-27 Method for treating neurodegenerative disorders
JP2000551761A JP4637351B2 (en) 1998-06-01 1999-05-27 Treatment of neurodegenerative diseases
DE69913520T DE69913520T2 (en) 1998-06-01 1999-05-27 TETRAHYDRONAPHTALENE COMPOUNDS AND THE USE THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
AT99928342T ATE255888T1 (en) 1998-06-01 1999-05-27 TETRAHYDRONAPHTALENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP99928342A EP1083889B1 (en) 1998-06-01 1999-05-27 Tetrahydronaphtalene compounds and their use for the treatment of neurodegenerative diseases
DK99928342T DK1083889T3 (en) 1998-06-01 1999-05-27 Tetrahydronaphthalene compounds and their use in the treatment of neurodegenerative diseases
AU45433/99A AU765142B2 (en) 1998-06-01 1999-05-27 Method for treating neurodegenerative disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8757798P 1998-06-01 1998-06-01
US60/087,577 1998-06-01

Publications (2)

Publication Number Publication Date
WO1999062505A2 WO1999062505A2 (en) 1999-12-09
WO1999062505A3 true WO1999062505A3 (en) 2000-04-06

Family

ID=22206004

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/011702 WO1999062505A2 (en) 1998-06-01 1999-05-27 Method for treating neurodegenerative disorders

Country Status (12)

Country Link
US (2) US6441049B2 (en)
EP (1) EP1083889B1 (en)
JP (1) JP4637351B2 (en)
AR (1) AR018431A1 (en)
AT (1) ATE255888T1 (en)
AU (1) AU765142B2 (en)
CA (1) CA2333951C (en)
DE (1) DE69913520T2 (en)
DK (1) DK1083889T3 (en)
ES (1) ES2212570T3 (en)
PT (1) PT1083889E (en)
WO (1) WO1999062505A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9108961B2 (en) 2010-05-17 2015-08-18 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
US6380224B1 (en) * 1999-07-28 2002-04-30 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
BR0016652A (en) 1999-12-23 2002-11-19 Neurochem Inc Methods to inhibit cerebral amyloid angiopathy, to treat a disease state characterized by cerebral amyloid angiopathy in an individual, and to diagnose cerebral amyloid angiopathy in an individual
JP2001261652A (en) * 2000-03-21 2001-09-26 Suntory Ltd Disubstituted iminoheterocyclic compound
WO2001073446A1 (en) * 2000-03-29 2001-10-04 Synaptica Limited Alpha 7 nicotinic receptor screening assays
US7049337B2 (en) * 2000-05-19 2006-05-23 Wayne State University Derivatives of 2-aminotetralins and pharmaceutical analogs thereof exhibiting differential CNS receptor activity and behavior
US20030092613A1 (en) * 2000-08-14 2003-05-15 Lee Daniel H. S. Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides
PL369895A1 (en) 2001-10-02 2005-05-02 Pharmacia & Upjohn Company Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
CA2466344A1 (en) 2001-11-09 2003-05-22 Pharmacia & Upjohn Company Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
NZ533259A (en) 2001-12-14 2007-10-26 Targacept Inc Methods and compositions for treatment of central nervous system disorders
DE10164139A1 (en) 2001-12-27 2003-07-10 Bayer Ag 2-heteroaryl carboxamides
US7045534B2 (en) * 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
JP2005523287A (en) * 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Azabicyclo compounds for disease treatment
US6858613B2 (en) * 2002-02-19 2005-02-22 Pfizer Inc. Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
JP2006501246A (en) 2002-08-30 2006-01-12 メモリー・ファーマシューティカルズ・コーポレイション Anabaseine derivatives useful in the treatment of neurodegenerative diseases
KR101129933B1 (en) 2002-09-25 2012-03-23 메모리 파마슈티칼스 코포레이션 Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
BR0315056A (en) * 2002-11-01 2005-08-16 Pharmacia & Upjohn Co Llc Compounds having both nicotinically alpha7 agonist activity and 5ht3 antagonist activity for the treatment of central nervous system disorders
US7273872B2 (en) * 2002-12-06 2007-09-25 The Feinstein Institute For Medical Research Inhibition of inflammation using α 7 receptor-binding cholinergic agonists
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
US20060149618A1 (en) * 2003-02-19 2006-07-06 Michael Balin System for providing private offers to customers of web sites
EP1635823A1 (en) * 2003-05-20 2006-03-22 TransTech Pharma Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
WO2005013910A2 (en) * 2003-08-07 2005-02-17 University Of South Florida Cholinergic modulation of microglial activation via alpha-7 nicotinic receptors
DK1678172T3 (en) 2003-10-15 2010-04-06 Targacept Inc Azabicyclic compounds for pain relief and treatment of central nervous system disorders
EP1541547A1 (en) * 2003-12-11 2005-06-15 Newron Pharmaceuticals S.p.A. Hydroxylamine derivatives
US20050170360A1 (en) * 2004-01-30 2005-08-04 Papke Roger L. Variant neuronal nicotinic alpha-7 receptor and methods of use
DE102004014841B4 (en) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Use of rotigotine for the treatment and prevention of Parkinson-Plus syndrome
JP4995075B2 (en) 2004-03-25 2012-08-08 メモリー・ファーマシューティカルズ・コーポレイション Indazole, benzothiazole, benzisothiazole, benzisoxazole, and their preparation and use
US9216966B2 (en) 2004-10-04 2015-12-22 John Manfredi Compounds for Alzheimer's disease
US7678823B2 (en) 2004-10-04 2010-03-16 Myriad Pharmaceticals, Inc. Compounds for alzheimer's disease
EP1917265B1 (en) 2005-08-22 2010-09-29 Targacept, Inc. HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF
AU2006294579A1 (en) * 2005-09-27 2007-04-05 Myriad Genetics, Inc. Pyrrole derivatives as therapeutic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
KR101439828B1 (en) 2005-11-30 2014-09-17 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
EP1978926A2 (en) * 2005-12-19 2008-10-15 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses thereof
US8846937B2 (en) * 2006-06-16 2014-09-30 University Of Kentucky Research Foundation Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors
FR2905009A1 (en) * 2006-08-18 2008-02-22 Servier Lab METHOD OF SCREENING COMPOUNDS WITH ANTI-AMYLOID PROPERTIES
EP2059238A4 (en) * 2006-09-07 2011-04-06 Myriad Genetics Inc Therapeutic compounds for diseases and disorders
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
CL2008000119A1 (en) 2007-01-16 2008-05-16 Wyeth Corp COMPOUNDS DERIVED FROM PIRAZOL, ANTAGONISTS OF THE NICOTINIC ACETILCOLINE RECEIVER; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS SENILE DEMENTIA, ALZHEIMER AND SCHIZOPHRENIA.
SA08290475B1 (en) 2007-08-02 2013-06-22 Targacept Inc (2S,3R)-N-(2-((3-Pyridinyl)Methyl)-1-Azabicyclo[2.2.2]Oct-3-yl)Benzofuran-2-Carboxamide, Novel Salt forms, and Methods of Use Thereof
MX2010003375A (en) 2007-10-01 2010-05-17 Comentis Inc Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease.
WO2009102962A2 (en) 2008-02-13 2009-08-20 Targacept, Inc. Combination of alpha 7 nicotinic agonists and antipsychotics
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP5805646B2 (en) 2009-09-30 2015-11-04 ブイティーブイ・セラピューティクス・エルエルシー Substituted imidazole derivatives for the treatment of Alzheimer's disease
DE102010020553A1 (en) 2010-05-14 2011-11-17 Bayer Schering Pharma Aktiengesellschaft Substituted 8-alkoxy-2-aminotetralin derivatives and their use
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
CN106074548A (en) 2010-09-23 2016-11-09 艾伯维巴哈马有限公司 The monohydrate of azaadamantane derivatives
FR2966827B1 (en) 2010-10-27 2014-08-22 Kimonella Ventures Ltd PEPTIDE COMPOUND USEFUL FOR INHIBITING AMYLOID PLATE FORMATION
WO2013111578A1 (en) * 2012-01-27 2013-08-01 パナソニック株式会社 Diagnosis method and diagnosis system for alzheimer's disease
WO2014012054A1 (en) 2012-07-13 2014-01-16 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patent
DK2882428T3 (en) * 2012-07-13 2019-04-15 Pain Therapeutics Inc PROCEDURE TO INHIBIT TAU PHOSPHORIZATION
US9387203B2 (en) 2012-07-20 2016-07-12 Bayer Pharma Aktiengesellschaft Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof
AU2013292046C1 (en) 2012-07-20 2018-03-15 Bayer Pharma Aktiengesellschaft Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
GB201303507D0 (en) * 2013-02-27 2013-04-10 Hollfelder Florian Assays
TW201617342A (en) 2014-07-11 2016-05-16 阿法馬根公司 Quinuclidines for modulating alpha 7 activity
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
WO2018067662A1 (en) * 2016-10-04 2018-04-12 University Of Miami Protein amyloidogenesis and related methods
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
JP7464591B2 (en) 2018-10-10 2024-04-09 ブイティーブイ・セラピューティクス・エルエルシー Metabolite of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine
CU24626B1 (en) 2019-12-26 2022-11-07 Centro Nac De Biopreparados PHARMACEUTICAL COMPOSITION BASED ON PROTEINS WITH NEUROPROTECTIVE, IMMUNOMODULATORY, ANTI-INFLAMMATORY AND ANTIMICROBIAL ACTIVITIES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH637363A5 (en) * 1977-11-24 1983-07-29 Sandoz Ag Process for preparing novel 2-aminotetralins
EP0360077A2 (en) * 1988-09-20 1990-03-28 Troponwerke GmbH & Co. KG Use of serotonin antagonists in the treatment of apoplexia cerebri

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554601A (en) 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US6689574B1 (en) * 1997-10-07 2004-02-10 Merck & Co., Inc. Assays for nuclear receptor agonists and antagonists using fluorescence resonance energy transfer
US6329159B1 (en) * 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
US6689578B2 (en) * 2001-12-06 2004-02-10 Paradigm Genetics, Inc. Methods for the identification of inhibitors of 5-aminolevulinate synthase as antibiotics

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH637363A5 (en) * 1977-11-24 1983-07-29 Sandoz Ag Process for preparing novel 2-aminotetralins
EP0360077A2 (en) * 1988-09-20 1990-03-28 Troponwerke GmbH & Co. KG Use of serotonin antagonists in the treatment of apoplexia cerebri

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AULD ET AL.: "Beta-Amyloid peptides as direct cholinergic neuromodulatorys : a missing link ?", TRENDS NEUROSCI., vol. 21, no. 1, January 1998 (1998-01-01), pages 43 - 49, XP000853850 *
ITOH ET AL.: "Dysfunction of cholinergic and dopaminergic neuronal systems in beta-amyloid protein-infused rats", J. NEUROCHEM., vol. 66, 1996, pages 1113 - 1117, XP002916315 *
KIHARA ET AL.: "Neuroprotective effect of nicotine-related substances against beta-amyloid cytotoxicity", NEUROSCI. RES., vol. suppl., no. 21, 1997, pages s158, XP002128692 *
KIHARA ET AL.: "Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity", ANN. NEUROL., vol. 42, no. 2, August 1997 (1997-08-01), pages 159 - 163, XP000853838 *
MAURICE ET AL.: "Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction", BRAIN RES., vol. 706, no. 2, 1996, pages 181 - 193, XP002128693 *
MCDERMED ET AL.: "Synthesis and pharmacology of some 2-aminotetralins. Dopamine receptor agonists", J. MED. CHEM., vol. 18, no. 4, 1975, pages 362 - 367, XP002067369 *
SALOMON ET AL.: "Nicotine inhibits amyloid formation by the beta-peptide", BIOCHEMISTRY, vol. 35, no. 42, 1996, pages 13568 - 13578, XP000857787 *
SJÖBERG ET AL.: "Neuronal nicotinic receptor activation : a promising strategy for the treatment of Alzheimer's disease ?", INT. J. GERIATRIC PSYCHOPHARMACOLOGY, vol. 1, no. 3, 1998, pages 145 - 149, XP002128695 *
ZAMANI ET AL.: "Nicotine modulates the neurtoxic effect of beta-amyloid protein(25-35) in hippocampal cultures", NEUROREPORT, vol. 8, no. 2, 20 January 1997 (1997-01-20), pages 513 - 517, XP002128694 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9108961B2 (en) 2010-05-17 2015-08-18 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride
US9273044B2 (en) 2010-05-17 2016-03-01 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9550767B2 (en) 2010-05-17 2017-01-24 Forum Pharmaceuticals, Inc. Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function

Also Published As

Publication number Publication date
AU765142B2 (en) 2003-09-11
WO1999062505A2 (en) 1999-12-09
AR018431A1 (en) 2001-11-14
CA2333951A1 (en) 1999-12-09
US20030130165A1 (en) 2003-07-10
EP1083889B1 (en) 2003-12-10
CA2333951C (en) 2012-02-28
ES2212570T3 (en) 2004-07-16
JP2002516853A (en) 2002-06-11
US6441049B2 (en) 2002-08-27
EP1083889A2 (en) 2001-03-21
DK1083889T3 (en) 2004-04-13
JP4637351B2 (en) 2011-02-23
DE69913520D1 (en) 2004-01-22
DE69913520T2 (en) 2004-11-25
ATE255888T1 (en) 2003-12-15
US20020013374A1 (en) 2002-01-31
AU4543399A (en) 1999-12-20
US7018797B2 (en) 2006-03-28
PT1083889E (en) 2004-04-30

Similar Documents

Publication Publication Date Title
WO1999062505A3 (en) Method for treating neurodegenerative disorders
AU3056297A (en) Techniques of treating neurodegenerative disorders by brain infusion
IL149890A0 (en) Tnt-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated
WO2001005390A3 (en) Method for treating chronic pain using mek inhibitors
EP1014881A4 (en) Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
EP0686629A3 (en) Cyclohexyl tachykinine receptor antagonists
IL148071A0 (en) Method for treatment of symptoms of central nervous system disorders
WO1999015159A3 (en) Methods for increasing apoe levels for the treatment of neurodegenerative disease
WO2003096983A3 (en) Method of treating dyslipidemic disorders
PL379989A1 (en) Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the same
AU2001238369A1 (en) Method for treating thyroid disorders
WO2001005392A3 (en) Method for treating chronic pain using mek inhibitors
AU2674797A (en) Method of treating movement disorders by brain infusion
WO2004014352A3 (en) Methods for treating carbonic anhydrase mediated disorders
ZA9711279B (en) Method for treating and preventing neurological disorders and promoting wound healing.
WO2006080549A3 (en) Method and composition for treating central nervous system disorders
AU1633500A (en) Composition and methods for inhibiting the formation of brain amyloid deposits
AU6244898A (en) (d)-methadone, a nonopioid analgesic
EP0730866A3 (en) Treatment of optic nerve disorders with prostanoic acid compounds
IL145696A0 (en) Method for the treatment of neurological or neuropsychiatric disorders
ZA982454B (en) Method for treatment of chronic bronchitis using indole compounds.
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
GB0215978D0 (en) Novel compounds
WO1996006604A3 (en) Methods for identifying and treating resistant tumors
IL121217A0 (en) Pharmaceutical composition for treating chronic progressive vascular diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 45433/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2000 551761

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2333951

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/011847

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1999928342

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999928342

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1999928342

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 45433/99

Country of ref document: AU